Clinical trial considerations: Why diversity matters…
February 15, 2024 | Diversity, Inclusion, clinical trials
Diversity in clinical trials is crucial for understanding diseases and developing new treatments. Here’s why diversity matters…
Clinical trials are crucial for understanding diseases and developing new treatments. For trials to truly benefit everyone, diversity among participants is key. But why does diversity matter?
Accurate results – Everyone’s genes, environment and lifestyles are different. Which is why it’s important that participants from different locations, and with differing ways of living are included; it helps in understanding how different populations may respond to treatment.
Health equity – Achieving health equity involves addressing social, economic and environmental factors that impact health outcomes. The principle behind health equity is that everyone should have the same access to healthcare, regardless of their background, race, ethnicity or circumstances, giving them a fair opportunity to be as healthy as possible.
Builds trust – Having a diverse representation of people participating in clinical trials helps to boost trust between healthcare providers, researchers and communities.
Hopefully we can agree that diversity in clinical trials is vitally important! So how can we ensure individuals feel seen, heard and respected? Here are a few things we always keep in mind when developing clinical trial support materials:
- Patient engagement – It’s important to fully understand the patient population we are creating for. By meeting with real people, there is potential to learn more about barriers to participation and what we can do to overcome them. For patients from diverse communities, we also consider different perceptions, the use of language and how information is received and acted upon. In our experience, the best way to do this is to engage with patients and ask for their feedback at every step of the process.
- Removing barriers – Some people face significant barriers that prevent them from being able to participate in a trial. These could be not having access to a local treatment centre or no way to get to a treatment centre if there is one. Financial burdens may also prevent someone from being able to take time out of work to take part in a trial or having the money to get to and from study visits. Digitalising trials can help to overcome some of these barriers by allowing patients to receive treatment, tests and assessments at home. Want to know more about how we can support you in navigating new digital strategies for clinical trials? We wrote a blog on this very topic!
- Create materials that represent a wide range of people – We ensure that variations in race, culture, age, gender, ethnicity, sexuality, and ability within any given target audience are always represented. And we do this via visual style or imagery, the words we use and how we localise the content, as well as the format of materials:
- Imagery – It can be difficult to achieve representative diversity in the imagery we use when there is such a range of body types and skin tones across the world. However, difficult doesn’t mean impossible. We recommend using illustrations as stylistically, they are better able to convey diversity.
- Localisation – In many cases, there may not be a one-size-fits-all approach to achieving diverse representation. This is why we never consider development of a single material to be sufficient. Instead, support materials should always be localised for all countries the study is planned for.
This doesn’t just mean translating the content though. It’s essential to also account for cultural adaptations that may be needed. Such as, are there technical limitations in some of your target countries? Do regional differences mean that some content may not be relatable across the board?
For example, here is how we created alternative food-related content for Latin America versus a more typical Western diet:
Diversity in clinical trials matters. Making sure participants feel represented matters. And representing diversity in clinical trial materials definitely matters. If you would like help in making sure every individual involved in your trial feels seen and appreciated, let’s talk.
This content was provided by Cuttsy + Cuttsy
Company Details
Latest Content from Cuttsy + Cuttsy
Designing with patients in mind: How to build more inclusive clinical trials
Discover how patient-centred design transforms inclusive clinical trials. Learn to overcome trial recruitment challenges by listening to patients and creating studies that fit real lives.
Why fresh patient voices are critical to improve clinical trials outcomes
Discover why diverse patient voices, especially first-time participants, are key to improving clinical trials. Boost recruitment, retention, and patient-centric research.
Using patient personas to add a personal touch to clinical trial recruitment and retention
Discover how patient personas can revolutionise clinical trial recruitment and retention. Personalise outreach, build trust, and improve patient engagement.
A month of insights: Key takeaways from May’s conferences
Explore key insights from some of May’s top healthcare conferences, covering patient engagement, health equity, co-creation, and tech innovation shaping clinical trials.
Cuttsy+Cuttsy and ISPEP highlight key patient insights in new clinical trials report
Explore how Cuttsy+Cuttsy and ISPEP are spotlighting patient engagement in clinical trials through a new global report.
Motivations that matter: Understanding clinical trial participation to create better research
Understanding why people join clinical trials is essential to improving recruitment and designing better research. Explores the diverse motivations driving participation — from altruism and hope for better health to...
Cuttsy+Cuttsy welcomes new team members and celebrates a familiar face returning
Cuttsy+Cuttsy proudly announces the expansion of its team with the addition of three new hires—Michelle, Jay, and Emily—and the welcome return of former team member Sally as Account Director.
AI and away we go: key insights from Reuters Pharma 2025
AI is revolutionising the pharmaceutical industry, as highlighted at Reuters Pharma 2025, with transformative applications across marketing, drug discovery, and patient engagement, despite challenges in adoption, regulation, and data trust.
Exciting updates from our content and strategy team
Cuttsy+Cuttsy celebrates new beginnings with the appointment of Oli Bailey as Strategy Director and recognises team excellence through several well-deserved promotions.
How is generative AI transforming clinical trials?
Discover how generative AI is revolutionising clinical trials, from enhancing patient recruitment to improving data analysis.